Type 2 Diabetes Mellitus Clinical Trial
Official title:
The Together on Diabetes Intervention
Verified date | January 2021 |
Source | Center for Diabetes, Copenhagen Municipality |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Danish healthcare system is universal and free of charge for Danish citizens, as all healthcare services are financed by general taxes. However, socioeconomic differences exist in access to healthcare services, treatment, and consequences of type 2-diabetes (T2D). Using a realistic evaluation approach, this study aimed to evaluate the implementation of a Danish peer support intervention, targeted on improving self-management and use of healthcare services among socially vulnerable people with type 2-diabetes ("peers"). The study focused on the mechanisms generating the intended outcomes. Further, how contextual factors in peers' everyday life facilitated or hindered the mechanisms to operate. The study design is a multi-method case study (n=9). Data include qualitative semi-structured interviews with four key groups of informants (peer, peer supporter, project manager, and a diabetes nurse). Each type of informant per case was interviewed (n=25) to obtain different perspectives of how the peers' interacted, and benefited from the intervention. All interviews were completed immediately after the after the 6-month intervention. Further, a quantitative survey was conducted among peers at baseline (N=9) and follow-up (N=9) to obtain information about how peers' individual contextual factors, such as their sociodemographic characteristics, co-morbidity, diabetes complications, social relations, and other life events influenced how they perceived and interacted in the intervention. Further, to measure improvements in their diabetes-self management (DSM) and use of healthcare services (outcomes). Questions from the Danish National Health Survey were used to measure DSM: (eating habits, physical activity,and medication intake). Use of healthcare services was measured by the number of times (during a 12-month period) the peers' attended diabetes controls at the GP; food therapist, and ophthalmologist or had other form of contacts with relevant health care services. All data were collected between February 2018 and April 2020. Hypothesis: 6-month individual face-to-face peer support provided by non-professional persons with T2D can improve self-management and use of healthcare services among socially vulnerable people with T2D if contextual factors such as peers' sociodemographic characteristics, health condition, and social relations facilitate their engagement in the intervention. Potential mechanisms that generate the expected outcomes might be: peers' motivation, trust, perceived beliefs and needs; and experience of being supported by the peer supporters.
Status | Completed |
Enrollment | 20 |
Est. completion date | May 1, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Peers: Inclusion Criteria: - Poorly regulated T2D - multi-morbidity - no employment - low/no education - no contact to the healthcare system - living alone with no/spare social network. Exclusion Criteria: - Poor regulated mental disease. Peer supporters Inclusion criteria: - Well-regulated T2D - Basic knowledge about T2D and the Danish healthcare system; - Good communication skills - Empathy - An interest in supporting a socially vulnerable person with T2D - Available two hours every second week for at least six-month (the intervention period). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Center for Diabetes, Copenhagen Municipality | Innovation Fund Denmark, Novo Nordisk A/S, The Danish Diabetes Association, University of Copenhagen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline, diet habits | Peers' diet habits (self-reported), Questionnaire data | Assessed among peers before study participation, 0 month | |
Primary | Change from Baseline, diet habits at 6 month | Improvements in the peers' diet habits (self-reported), Questionnaire data | Assessed among peers after study participation, at 6 month | |
Primary | Baseline, physical activity (training) | Peers' physical activity level measured by time spend in a typical week on physiclal acitivty were they are breathing (eg. running, exercise gymnastics or ball sports) (self-reported), Questionnaire data | Assessed among peers before study participation, 0 month | |
Primary | Change from Baseline, physical activity (training) at 6 month | Improvements in the peers' physical activity level measured by time spend in a typical week on physiclal acitivty were they are breathing (eg. running, exercise gymnastics or ball sports) (self-reported), Questionnaire data | Assessed among peers after study participation, at 6 month | |
Primary | Baseline, physical activity (everyday activities) | Peers' physical activity level measured by time spend in a typical week on everyday activities (eg. walking, cycling or gardening? (self-reported), Questionnaire data | Assessed among peers before study participation, 0 month | |
Primary | Change from Baseline, physical activity (everyday activities) at 6 month | Improvements in the peers' physical activity level measured by time spend in a typical week on everyday activities (eg. walking, cycling or gardening? (self-reported), Questionnaire data | Assessed among peers after study participation, at 6 month | |
Primary | Baseline, diabetes medication adherence | Peers' diabetes medication adherence measured by how often they forget to take their prescribed diabetes medication (self-reported), Questionnaire data | Assessed among peers before study participation, at 0 month | |
Primary | Baseline, diabetes medication adherence | Improvements in peers' diabetes medication adherence measured by how often they forget to take their prescribed diabetes medication (self-reported), Questionnaire data | Assessed among peers before study participation, at 0 month | |
Primary | Baseline, Use of healthcare services (diabetes controls at the GP) | Number of diabetes controls at GP (self-reported), Questionnaire data | ssessed among peers before study participation, 0 month | |
Primary | Change from baseline, use of healthcare services (diabetes controls at the GP) | Improvements in the number of diabetes controls at the GP (self-reported), Questionnaire data | Assessed among peers after study participation, at 6 month | |
Primary | Baseline, use of healthcare services (diabetes controls at the foot therapist) | Number of diabetes controls at the food therapist) (self-reported), Questionnaire data | Assessed among peers before study participation, at 0 month | |
Primary | Change from baseline, use of healthcare services (diabetes controls at the foot therapist) | Improvements in the number of diabetes controls at the food therapist) (self-reported), Questionnaire data | Assessed among peers after study participation, at 6 month | |
Primary | Baseline, use of healthcare services (diabetes controls at the ophthalmologist ) | Number of diabetes controls at the ophthalmologist ) (self-reported), Questionnaire data | Assessed among peers before study participation, at 0 month | |
Primary | Change from baseline, use of healthcare services (diabetes controls at the ophthalmologist ) | Improvements in the number of diabetes controls at the ophthalmologist ) (self-reported), Questionnaire data | Assessed among peers after study participation, at 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|